Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report sent to investors on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Trading Up 2.0 %

Shares of TTNP stock opened at $6.64 on Friday. The stock has a 50 day simple moving average of $6.84 and a two-hundred day simple moving average of $6.81. Titan Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $16.59.

Titan Pharmaceuticals (NASDAQ:TTNP) last issued its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) earnings per share for the quarter. Titan Pharmaceuticals had a negative return on equity of 99.96% and a negative net margin of 2,014.71%.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.